Source comparison
CJC-1295 vs Other GHRH Analogues in Long-Term Research
Sermorelin, tesamorelin, and Modified GRF 1-29 (CJC-1295 without DAC) all stimulate endogenous GH release through GHRH receptor activation, but none achieve the extended plasma retention of DAC-modified CJC-1295. Sermorelin has a plasma half-life under 10 minu
This comparison does not assign a generated winner or score.
- Sermorelin, tesamorelin, and Modified GRF 1-29 (CJC-1295 without DAC) all stimulate endogenous GH release through GHRH receptor activation, but none achieve the extended plasma retention of DAC-modified CJC-1295. Sermorelin has a plasma half-life under 10 minutes. Viable for acute GH pulse studies, not sustained-release protocols. Tesamorelin extends stability slightly through trans-3-hexenoic acid modification, but still requires daily dosing to maintain therapeutic effect.
- Modified GRF 1-29. Often sold as 'CJC-1295 no DAC'. Is chemically identical to CJC-1295 except for the absence of the DAC group. It binds GHRH receptors with equal affinity but degrades within 30 minutes via DPP-IV cleavage at the alanine-2 position. This makes it useful for pulsatile GH studies where rapid clearance is desirable, but fundamentally incompatible with extended half-life research.
- Our team has supplied peptides for comparative pharmacokinetic trials, and the pattern is consistent: researchers choose CJC-1295 with DAC when the study design requires once-weekly dosing, stable plasma levels, and minimised injection frequency. For acute pulse studies or receptor occupancy experiments, Modified GRF 1-29 or sermorelin remain the standard. The choice depends entirely on whether the research question requires sustained or transient GH elevation.